Targets › CD70
29 programs from 21 companies in 39 trials: 29 Phase 1, 9 Phase 2, 1 Phase 3; Oncology, Immunology, Genitourinary; next expected readout Nov 2026.
Expressed at the plasma membrane of B cells, it is the ligand of the CD27 receptor which is specifically expressed at the surface of T cells. The CD70-CD27 signaling pathway mediates antigen-specific T cell activation and expansion which in turn provides immune surveillance of B cells. (UniProt, P32970)
Open in Phaseline: the race on CD70, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Alpine Immune Sciences | Povetacicept (ALPN-303) Dual CD27/CD70 co-stimulation inhibitor | CD27, CD70 | Phase 3 | Immunoglobulin A Nephropathy | Jan 2028 |
| RenJi Hospital | [18F]F-RESCA-RCCB6 Trop2/HER2-targeted PET imaging agent | CD70, TROP2, TACSTD2, ERBB2 | Phase 2 | Urologic Neoplasms; Renal Cancer; Solid Tumor; Breast Cancer | Nov 2026 |
| RenJi Hospital | [18F]F-RESCA-R8B4 CD70-targeted immunoPET imaging agent | CD70 | Phase 2 | Renal Cancer | Dec 2026 |
| RenJi Hospital | [18F]F-RESCA-RD06 CD70-targeted immunoPET imaging agent | CD70 | Phase 2 | Renal Cancer | Dec 2026 |
| RenJi Hospital | [68Ga]Ga-NOTA-R8B4 CD70-targeted immunoPET imaging agent | CD70, TROP2 | Phase 2 | Renal Cancer; Solid Tumor | Dec 2026 |
| OncoVerity | Cusatuzumab CD70 antigen inhibitor | CD70 | Phase 2 | Leukemia, Myeloid, Acute | Jan 2027 |
| Chongqing Precision Biotech | CD70 CAR-T cells anti-CD70 CAR-T cell therapy | CD70 | Phase 1 | Ovarian Cancer; Metastatic Tumor | Dec 2026 |
| Chinese PLA General Hospital | CD70-targeting CAR-T cells CD70-targeted CAR-T cell therapy | CD70 | Phase 1 | Solid Tumor, Adult; Lymphoma | Dec 2026 |
| Beijing Biotech | EB-701/CA9-NK Dual-target CD70/CAIX CAR-NK cells | CD70, CA9 | Phase 1 | Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Apr 2027 |
| Tianjin Medical University Cancer Institute and Hospital | CHT101 anti-CD70 CAR-T cell therapy | CD70 | Phase 1 | Relapsed / Refractory Solid Tumor; Peripheral T-cell Lymphoma | Apr 2027 |
| Pfizer | SEA-CD70 anti-CD70 antibody-drug conjugate | CD70 | Phase 1 | Myelodysplastic Syndrome | Jul 2027 |
| The Children's Hospital of Zhejiang University School of Medicine | anti-BCMA/CD70 CAR-T cells CAR-T cell therapy targeting BCMA and CD70 | BCMA, CD70 | Phase 1 | Multi-Drug Resistant Nephrotic Syndrome | Jul 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | CD70 CAR-NK Anti-CD70 CAR-NK cell therapy | CD70 | Phase 1 | Relapsed/Refractory T-cell Lymphoma | Nov 2027 |
| University of Florida | 8R-70CAR T cells IL-8 receptor (CXCR2)-modified CD70 CAR T cell therapy | CXCR2, CD70 | Phase 1 | Glioblastoma Multiforme; Brain Metastases | Dec 2027 |
| Qilu Pharmaceutical | QLS2309 anti-CD70 antibody-drug conjugate | CD70 | Phase 1 | Relapsed or Refractory Hematologic Malignancies | Dec 2027 |
| Aibin Liang,MD,Ph.D. | dualCAR-NK19/70 cell anti-CD19/CD70 CAR-NK cell therapy | CD19, CD70 | Phase 1 | Refractory or Relapsed B-cell Non-Hodgkin Lymphoma | Jan 2028 |
| M.D. Anderson Cancer Center | TGFBR-2 KO CD70 CAR NK Allogeneic TGF-β receptor 2 knockout CD70-targeted CAR NK cell therapy | CD70 | Phase 1 | Clear Cell Carcinoma | Feb 2028 |
| Allogene Therapeutics | ALLO-329 Allogeneic dual CAR T-cell therapy targeting CD19 and CD70 | CD19, CD70 | Phase 1 | Systemic Lupus Erythematosus (With and Without Nephritis) | Feb 2028 |
| The Children's Hospital of Zhejiang University School of Medicine | anti-BCMA/CD70-CAR-T cells CAR-T cells targeting BCMA and CD70 | BCMA, CD70 | Phase 1 | CAR T Cell Therapy | Apr 2028 |
| Chongqing Precision Biotech | BCMA/CD70 CAR-T cells Dual-targeted CAR-T cell therapy against BCMA and CD70 | TNFRSF17, CD70 | Phase 1 | Systemic Lupus Erythematosus | Aug 2028 |
| Chongqing Precision Biotech | BCMA/CD70-targeted CAR-T Dual-targeted CAR-T cell therapy against BCMA and CD70 | BCMA, CD70 | Phase 1 | Juvenile Dermatomyositis (JDM) | Sep 2028 |
| National Cancer Institute (NCI) | Anti-hCD70 CAR transduced PBL CD70-binding chimeric antigen receptor (CAR) on transduced peripheral blood lymphocytes | CD70 | Phase 1 | Pancreatic Cancer | Jan 2029 |
| Hrain Biotechnology | Anti-Human CD70 T-Cell Injection Anti-CD70 CAR-T cell therapy | CD70 | Phase 1 | Renal Cell Carcinoma (RCC) | Jun 2029 |
| Baylor College of Medicine | CD70.CAR CD70-targeting chimeric antigen receptor (CAR) T cell therapy | CD70 | Phase 1 | Leukemia, Myeloid, Acute | Jun 2029 |
| Allogene Therapeutics | ALLO-316 Allogeneic CAR T cell therapy targeting CD70 | CD70 | Phase 1 | Advanced/Metastatic Clear Cell Renal Cell Carcinoma | Jan 2030 |
| St. Jude Children's Research Hospital | CD70-CAR T cell infusion (Autologous) anti-CD70 CAR-T cell therapy | CD70 | Phase 1 | Hematologic Malignancy | Jul 2030 |
| M.D. Anderson Cancer Center | CAR.70/IL15-transduced CB-NK cells CAR-T cell therapy targeting CD70 with IL-15 transduction in natural killer cells derived | CD70 | Phase 1 | B-Cell Lymphoma | Aug 2030 |
| Adicet Therapeutics | ADI-270 anti-CD70 CAR-T cell therapy (engineered gamma-delta Vδ1 T cells) | CD70 | Phase 1 | Clear Cell Renal Cell Carcinoma | – |
| Peking University Cancer Hospital & Institute | CGC738 CD70-targeted CAR-NKT cell therapy | CD70 | Phase 1 | Advanced Malignant Solid Tumors | – |
Renal Cancer (4) Leukemia, Myeloid, Acute (4) Solid Tumor (2) Relapsed / Refractory Solid Tumor (1) Peripheral T-cell Lymphoma (1) Refractory or Relapsed B-cell Non-Hodgkin Lymphoma (1) Advanced/Metastatic Clear Cell Renal Cell Carcinoma (1) Glioblastoma Multiforme (1) Brain Metastases (1) Myelodysplastic Syndrome (1) Solid Tumor, Adult (1) Lymphoma (1)
other (10), small molecule (9), mixed (7), protein or peptide (2), antibody (1)
RenJi Hospital (4) Chongqing Precision Biotech (3) Allogene Therapeutics (2) M.D. Anderson Cancer Center (2) The Children's Hospital of Zhejiang University School of Medicine (2) Tianjin Medical University Cancer Institute and Hospital (1) Aibin Liang,MD,Ph.D. (1) University of Florida (1) Pfizer (1) Chinese PLA General Hospital (1) Beijing Biotech (1) Alpine Immune Sciences (1) St. Jude Children's Research Hospital (1) Baylor College of Medicine (1) OncoVerity (1) Qilu Pharmaceutical (1) National Cancer Institute (NCI) (1) Peking University Cancer Hospital & Institute (1) Hrain Biotechnology (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
BCMA (3) CD19 (2) TROP2 (2) CXCR2 (1) CA9 (1) TACSTD2 (1) ERBB2 (1) CD27 (1) TNFRSF17 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.